The Network of Hematopoietic Cytokines

Abstract Cell viability, multiplication, and differentiation to the various hematopoietic cell lineages are induced by a multigene cytokine family, and hematopoiesis is controlled by a network of interactions between these cytokines. This network includes positive regulators such as colony-stimulating factors and interleukins, and negative regulators such as transforming growth factor-β and tumor necrosis factor. The functioning of the network requires an appropriate balance between positive and negative regulators, and the selective regulation of programed cell death (apoptosis) by interaction of cytokines with their receptors. The cytokine network, which has arisen during evolution, allows considerable flexibility, depending on which part of the network is activated, and the ready amplification of response to a particular stimulus. This amplification occurs by autoregulation and transregulation of genes for the hematopoietic cytokines. There is also a transregulation by these cytokines of cytokine receptors. In addition to the flexibility of this network, both for response to present day infections and to infections that may develop in the future, a network may also be necessary to stabilize the whole system. The existence of a network and the cytokine-receptor regulation of apoptosis has to be taken into account in the clinical use of cytokines for therapy. Cytokines that regulate hematopoiesis induce the expression of genes for transcription factors. Cytokine signaling through transcription factors can thus ensure the autoregulation and transregulation of cytokine and receptor genes that occur in the network. Interactions between the cytokine network and transcription factors can also ensure production of specific cell types and stability of the differentiated State.

[1]  S. de Vos,et al.  Transforming growth factor-beta 1 interferes with the proliferation-inducing activity of stem cell factor in myelogenous leukemia blasts through functional down-regulation of the c-kit proto-oncogene product. , 1993, Cancer research.

[2]  T. Hirano,et al.  Production of interleukin 6 and its relation to the macrophage differentiation of mouse myeloid leukemia cells (M1) treated with differentiation-inducing factor and 1 alpha,25-dihydroxyvitamin D3. , 1989, Biochemical and biophysical research communications.

[3]  O. Ottmann,et al.  Differential proliferative effects of transforming growth factor-beta on human hematopoietic progenitor cells. , 1988, Journal of immunology.

[4]  J. Lotem,et al.  Induction of genes for transcription factors by normal hematopoietic regulatory proteins in the differentiation of myeloid leukemic cells. , 1990, Leukemia.

[5]  L. Sachs,et al.  FORMATION OF PURE SUSPENSIONS OF MAST CELLS IN TISSUE CULTURE BY DIFFERENTIATION OF LYMPHOID CELLS FROM THE MOUSE THYMUS. , 1963, Journal of the National Cancer Institute.

[6]  L. Sachs The molecular control of blood cell development. , 1987, Science.

[7]  I. Kawashima,et al.  Interleukin-11: a novel stroma-derived cytokine. , 1992, Progress in growth factor research.

[8]  L. Sachs Growth, differentiation and the reversal of malignancy. , 1986, Scientific American.

[9]  R. Kamen,et al.  The human hematopoietic colony-stimulating factors. , 1987, Science.

[10]  J. Lotem,et al.  Inhibition of specific pathways of myeloid cell differentiation by an activated Hox-2.4 homeobox gene. , 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[11]  W. Paul,et al.  Hematopoietin sub-family classification based on size, gene organization and sequence homology , 1993, Current Biology.

[12]  C. Peschle,et al.  Adoptive immunotherapy with high-dose interleukin-2: kinetics of circulating progenitors correlate with interleukin-6, granulocyte colony-stimulating factor level. , 1991, Blood.

[13]  L. Sachs,et al.  The continued requirement for inducer for the development of macrophage and granulocyte colonies , 1968, Journal of cellular physiology.

[14]  F. Ruscetti,et al.  Transforming growth factor beta selectively inhibits normal and leukemic human bone marrow cell growth in vitro. , 1988, Blood.

[15]  J. Ihle,et al.  Procedures for the purification of interleukin 3 to homogeneity. , 1982, Journal of immunology.

[16]  J. Lipton,et al.  Separation of different molecular forms of macrophage‐ and granulocyte‐inducing proteins for normal and leukemic myeloid cells , 1980, International journal of cancer.

[17]  J. Bazan Neuropoietic cytokines in the hematopoietic fold , 1991, Neuron.

[18]  J. Lotem,et al.  The network of hemopoietic regulatory proteins in myeloid cell differentiation. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[19]  J. Lotem,et al.  Indirect induction of differentiation of normal and leukemic myeloid cells by recombinant interleukin 1. , 1989, Leukemia research.

[20]  S. Akira,et al.  Interleukin-6 and its receptor: a paradigm for cytokines. , 1992, Science.

[21]  J. Lotem,et al.  Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells. , 1992, Blood.

[22]  T. Mosmann,et al.  IL-10 inhibits cytokine production by activated macrophages. , 1991, Journal of immunology.

[23]  J. B. Blacklock,et al.  Cytokine Responses to Intraventricular Injection of Interleukin 2 into Patients with Leptomeningeal Carcinomatosis: Rapid Induction of Tumor Necrosis Factor α, Interleukin 1β, Interleukin 6, γ-Interferon, and Soluble Interleukin 2 Receptor (Mr 55,000 Protein) , 1992 .

[24]  J. Lotem,et al.  Selective regulation of the activity of different hematopoietic regulatory proteins by transforming growth factor beta 1 in normal and leukemic myeloid cells. , 1990, Blood.

[25]  T. Rose,et al.  Oncostatin M is a differentiation factor for myeloid leukemia cells. , 1992, Journal of immunology.

[26]  N. Shen,et al.  Apoptosis and DNA fragmentation precede TNF‐induced cytolysis in U937 cells , 1992, Journal of cellular biochemistry.

[27]  D. Metcalf,et al.  The growth of mouse bone marrow cells in vitro. , 1966, The Australian journal of experimental biology and medical science.

[28]  L. Sachs,et al.  The cloning of normal "mast" cells in tissue culture. , 1965, Journal of cellular physiology.

[29]  H. Asaoku,et al.  Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. , 1989, Blood.

[30]  K. Onozaki,et al.  Contribution of IL-6 to the antiproliferative effect of IL-1 and tumor necrosis factor on tumor cell lines. , 1989, Journal of immunology.

[31]  S. Jacobsen,et al.  Transforming growth factor-beta trans-modulates the expression of colony stimulating factor receptors on murine hematopoietic progenitor cell lines. , 1991, Blood.

[32]  J. Hatzfeld,et al.  Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor beta 1 or Rb oligonucleotides , 1991, The Journal of experimental medicine.

[33]  K. Takeda,et al.  Identity of differentiation inducing factor and tumour necrosis factor , 1986, Nature.

[34]  J. Lotem,et al.  Role of different normal hematopoietic regulatory proteins in the differentiation of myeloid leukemic cells , 1988, International journal of cancer.

[35]  L. Sachs,et al.  The induction of clones of normal mast cells by a substance from conditioned medium. , 1966, Experimental cell research.

[36]  J. Lotem,et al.  Rescue from programmed cell death in leukemic and normal myeloid cells. , 1991, Blood.

[37]  U. Gullberg,et al.  Characterization of a relationship between the T‐lymphocyte derived differentiation inducing factor (DIF) and lymphotoxin: A common receptor system for DIF, lymphotoxin and tumor necrosis factor downregulated by phorbol diesters , 1987, European journal of haematology.

[38]  J. Abrams,et al.  Role of interleukin 6 (IL-6) in protection from lethal irradiation and in endocrine responses to IL-1 and tumor necrosis factor , 1992, The Journal of experimental medicine.

[39]  J. Lotem,et al.  Coupling of growth and differentiation in normal myeloid precursors and the breakdown of this coupling in leukemia , 1983, International journal of cancer.

[40]  J. Bonner,et al.  Differentiation , 1968, Nature.

[41]  A. Ganser,et al.  In vivo administration of recombinant human interleukin-3 elicits an acute phase response involving endogenous synthesis of interleukin-6. , 1991, European cytokine network.

[42]  K. Ohta,et al.  Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. , 1993, Cancer research.

[43]  L. Sachs,et al.  Feedback inhibition of the development of macrophage and granulocyte colonies. I. Inhibition by macrophage. , 1967, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Goeddel,et al.  Genomic cloning and heterologous expression of human differentiation-stimulating factor. , 1989, DNA.

[45]  A. Kelso,et al.  Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). , 1987, The EMBO journal.

[46]  G. Yancopoulos,et al.  Ciliary neurotrophic factor and its receptor complex. , 1992, Progress in growth factor research.

[47]  J. Lotem,et al.  Autoregulation of interleukin 6 and granulocyte-macrophage colony-stimulating factor in the differentiation of myeloid leukemic cells , 1989, Molecular and cellular biology.

[48]  J. Lotem,et al.  Mechanisms that uncouple growth and differentiation in myeloid leukemia cells: restoration of requirement for normal growth-inducing protein without restoring induction of differentiation-inducing protein. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[49]  T. Kishimoto,et al.  Cytokine receptors and signal transduction , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  T. Hirano,et al.  Antiviral action of tumor necrosis factor in human fibroblasts is not mediated by B cell stimulatory factor 2/IFN-beta 2, and is inhibited by specific antibodies to IFN-beta. , 1988, Journal of immunology.

[51]  A. Kimchi,et al.  Autocrine β-related interferon controls c-myc suppression and growth arrest during hematopoietic cell differentiation , 1986, Cell.

[52]  J. Lotem,et al.  In vivo control of differentiation of myeloid leukemic cells by recombinant granulocyte-macrophage colony-stimulating factor and interleukin 3. , 1988, Blood.

[53]  J. Lotem,et al.  Regulation of cell‐surface receptors for hematopoietic differentiation‐inducing protein MGI‐2 on normal and leukemic myeloid cells , 1987, International journal of cancer.

[54]  A. Miyajima,et al.  Common subunits of cytokine receptors and the functional redundancy of cytokines. , 1992, Trends in biochemical sciences.

[55]  L. Sachs,et al.  Characterization of the inducer required for the development of macrophage and granulocyte colonies. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[56]  D. Metcalf Granulocyte-macrophage colony-stimulating factors , 1985, Cell.

[57]  J. Lotem,et al.  Induction of dependence on hematopoietic proteins for viability and receptor upregulation in differentiating myeloid leukemic cells. , 1989, Blood.